Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metagenomi Therapeutics, Inc.MGX · Entity 7270 | Chief Financial Officer | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metagenomi Therapeutics, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,580 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 1,911 · Balance 206,580 F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 19:34 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,911 | $1.16 | $2,213.70 |
DisclosureSEC source: 0001193125-26-387786 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,580 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 15:23 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 2,884 | $1.30 | $3,746.32 |
DisclosureSEC source: 0001193125-26-265335 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,491 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024 and April 1, 2025, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 17:40 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001193125-26-141867 · ownership.xml · derivative · entry 2 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2036-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 17:40 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-141867 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,375 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:16 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,581 | $1.60 | $2,529.60 |
DisclosureSEC source: 0001193125-26-098824 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,375 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| December 05, 2025 Filed Dec 8, 2025 18:49 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,576 | $1.77 | $2,792.51 |
DisclosureSEC source: 0001193125-25-310953 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,956 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:32 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 120,000 | $1.60 | $192,000.00 |
DisclosureSEC source: 0001193125-25-304218 · ownership.xml · nonDerivative · entry 2 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,532 F2 · kind: These shares represent RSUs. 50% of the RSUs shall vest on December 5, 2026, with the remainder vesting on December 5, 2027, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| September 05, 2025 Filed Dec 2, 2025 00:32 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,576 | $1.81 | $2,852.56 |
DisclosureSEC source: 0001193125-25-304218 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,532 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units ("RSUs") granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 22:54 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,576 | $1.75 | $2,758.00 |
DisclosureSEC source: 0000950170-25-083949 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,108 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:58 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-050103 · ownership.xml · derivative · entry 2 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,000 Underlying: Common Stock · 84,000 shares Expires 2035-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:58 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050103 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,684 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 21:36 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,808 | $1.87 | $3,389.64 |
DisclosureSEC source: 0000950170-25-035565 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,684 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $1.85 to $1.90, inclusive. The reporting person undertakes to provide to Metagenomi, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 21:24 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 1,559 | $1.86 | $2,899.74 |
DisclosureSEC source: 0000950170-24-134124 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,492 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. Read SEC document |
| September 05, 2024 Filed Sep 6, 2024 21:14 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 6,265 | $2.88 | $18,043.20 |
DisclosureSEC source: 0000950170-24-104439 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,051 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. F2 · price: The shares were sold in multiple transactions ranging from $2.80 to $2.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shars sold at each price. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:52 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 291,450 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000950170-24-041537 · ownership.xml · derivative · entry 2 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,450 Underlying: Common Stock · 291,450 shares Expires 2034-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on September 18, 2024, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:52 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 69,316 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041537 · ownership.xml · nonDerivative · entry 1 Wapnick Pamela · CIK 0001995657 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,316 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on September 5, 2024, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.